Myeloablative chemotherapy in testicular cancer patient Case report

Main Article Content

Karolina Furgała
Zuzanna Smuniewska
Dawid Sigorski
Maciej Michalak
Lubomir Bodnar

Abstract

Chemotherapy is the standard treatment for metastatic testicular cancers. The autologous hematopoietic stem cell transplantation is a salvage option for relapsed patients. The paper presents a case of a 20-year-old patient with stage IIIC non-seminoma treated with BEP chemotherapy and autologous transplantation of stem cells, which allowed to achieve durable remission.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Furgała K, Smuniewska Z, Sigorski D, Michalak M, Bodnar L. Myeloablative chemotherapy in testicular cancer patient. OncoReview [Internet]. 2021Mar.24 [cited 2024Mar.28];11(1(41):19-1. Available from: https://www.journalsmededu.pl/index.php/OncoReview/article/view/1195
Section
HEMATO-ONCOLOGY

References

1. Mead GM, Stenning SP; Clinical Oncology Editorial. The International Germ Cell Consensus Classification: A New Prognostic Factor-Based Staging Classification for Metastatic Germ Cell Tumours. Clin Oncol (R Coll Radiol). 1997; 9(4): 207-9.
2. Einhorn LH, Williams SD, Chamness A et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007; 357: 340-8.
3. McHugh DJ, Feldman DR. Conventional-dose versus high-dose chemotherapy for relapsed germ cell tumors. Adv Urol. 2018; 2018:7272541.
4. Lorch A, Bascoul-Mollevi C, Kramar A et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011; 29: 2178-84.
5. Feldman DR, Sheinfeld J, Bajorin DF et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010; 28: 1706-13.